New Drug Approvals

OCTOBER 12, 2024

ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease. Tramiprosate was reported to inhibit Aβ42 aggregation into toxic oligomers ( Gervais et al.,

Pharmacokinetics 62

Pharmacokinetics Small Molecule Disease Licensing 62

Alta Sciences

JUNE 27, 2023

Cancer Treatments, Clinical Trials, and the Motivation to Innovate nbartlett Tue, 06/27/2023 - 20:58 Getting to the Heart of Science with Michelle Newby At the heart of science are stories—stories of courage, challenges, successes, lessons, and people. Q: What was your cancer diagnosis and was treatment options were you given?

Clinical Trials 40

Clinical Trials Trials Treatment Science 40

The Pharma Data

DECEMBER 29, 2020

Primary Aldosteronism Testing Rare in Treatment-Resistant HTN. 29, 2020 — Patients with apparent treatment-resistant hypertension are rarely tested for primary aldosteronism, according to a study published online Dec. Veterans Health Administration with apparent treatment-resistant hypertension from 2000 to 2017.

Treatment 52

Treatment International Therapies Research 52

The Pharma Data

DECEMBER 17, 2020

18, 2020 /PRNewswire/ — Camurus AB (NASDAQ STO: CAMX) announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal ® prolonged release buprenorphine for the treatment of opioid dependence in adults and adolescents from 16 years of age. LUND, Sweden , Dec. About Buvidal.

Treatment 52

Treatment Clinical Trials International Pharmaceutical Companies 52

New Drug Approvals

NOVEMBER 13, 2023

WO 2017/208267A1, WO 2020/250133 Al and WO 2022/024072A1, which are hereby incorporated by reference, disclose methods of use of the compound of Formula I for the treatment of Parkinson’s disease, synucleinopathies and Alzheimer’s disease (AD) respectively. amcrasto@amcrasto /////////// Ref [1].

Treatment 62

Treatment Disease Therapies Production 62

Drug Target Review

JANUARY 25, 2024

These findings offer a novel strategy for developing targeted treatments for triple-negative breast cancer, which currently has no approved options. The team also observed that the drug prevented in vitro cancer stem cells from self-renewing, which is a characteristic of aggressive cancer cells that supports treatment resistance.

Treatment 106

Treatment Clinical Trials Research Science 106

The Pharma Data

MAY 1, 2023

In 2017, representatives from governments, global health organizations, public health bodies, academia, the private sector and civil society united around a call for action towards defeating meningitis. This primarily links with the following pillars/strategic goals of the roadmap.

Treatment 40

Treatment Government Vaccine International 40

The Pharma Data

APRIL 7, 2022

It may also limit coverage for any future approved treatment in the class. When additional data from this new class of treatments become available, Biogen urges CMS to reconsider today’s decision for all FDA-approved amyloid-beta targeting therapies. ADUHELM is indicated for the treatment of Alzheimer’s disease.

Therapies 52

Therapies Treatment Disease FDA Approval 52

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. iii Current treatment options have limited efficacy in terms of weight loss or are often associated with adverse events. “We

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

NOVEMBER 26, 2020

26, 2020 — In isolated areas of the United States, nurse practitioners are filling an important role in helping people access treatment for opioid addiction, according to a Washington State University (WSU) study. THURSDAY, Nov.

Nurses 52

Nurses Treatment Doctors Drugs 52

The Pharma Data

FEBRUARY 8, 2021

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. The recruitment period for the study spanned from December 2015 to July 2017. 3 Dual primary endpoints of the study were OS and rPFS.1 About ERLEADA ® (apalutamide).

Treatment 52

Treatment Pharmaceutical Companies Therapies Pharmaceuticals 52

The Pharma Data

FEBRUARY 22, 2021

Efanesoctocog alfa, a novel and investigational factor VIII therapy independent of von Willebrand Factor, is designed to provide near-normal factor activity levels for the majority of the week in a once-weekly prophylactic treatment regimen. Sanofi and Sobi collaborate on the development and commercialization of efanesoctocog alfa.

FDA 52

FDA Treatment Therapies International 52

Drug Target Review

JULY 9, 2024

Bowel cancer is the fourth most common cancer in the UK, accounting for 11 percent of all new cancer cases from 2017 to 2019 1 , and is the second most common cause of cancer death in the UK, accounting for 10 percent of all cancer deaths in the same time period. This study was published in Nature Genetics.

Regulations 106

Regulations DNA Treatment Research 106

The Pharma Data

NOVEMBER 24, 2020

25, 2020 /CNW/ – On August 21, 2020 , Health Canada approved Lynparza® (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM- mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).

Treatment 52

Treatment DNA Trials Therapies 52

The Pharma Data

JUNE 7, 2022

based production in support of its COVID-19 oral treatment, PAXLOVID TM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets). increasing Pfizer’s capability to produce and supply treatments and medicines for patients in the U.S. and has manufactured almost 17 million treatment courses total. and around the world.

Treatment 40

Treatment Vaccine Production Pharmaceuticals 40

The Pharma Data

MARCH 9, 2022

The most common treatment-emergent adverse events (>5% of participants overall) were headache, arthralgia, fall, and back pain. Dietmar Berger, MD, PhD Global Head of Development and Chief Medical Officer , Sanofi “While advances have been made in the treatment of hemophilia, unmet medical needs still exist.

Treatment 52

Treatment Pharmacokinetics Therapies FDA 52

Drug Target Review

JUNE 19, 2024

Our goal is to stand on the shoulders of giants and advance this exciting and new field of medicine, so that it can deliver valuable treatments to patients. How do you envision the future of cell therapy and its potential impact on medical treatments and healthcare? SVRA) in April 2017. from May 2017 until December 2022.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Target Review

AUGUST 16, 2023

Cancer remains a major global health concern, often diagnosed at advanced stages when treatment options and survival rates are limited. Suspicious findings can prompt further evaluation and definitive diagnosis, enabling timely treatment and improved patient outcomes. References 1. Jillian Phallen. DOI:10.1126/scitranslmed.aan2415

DNA 98

DNA Disease Therapies Treatment 98

Conversations in Drug Development Trends

AUGUST 10, 2023

As one of the more recent fields to emerge in the clinical space, psychedelics have gained significant traction as a potential treatment for various neuropsychiatric diseases. Psychedelic Research at Worldwide Since 2017, Worldwide Clinical Trials have supported a myriad of sponsors leading the way in psychedelic research programs.

Science 98

Science Clinical Trials Trials Clinical Research 98

Common Sense for Drug Policy Blog

NOVEMBER 7, 2023

2017 ; Levengood et al., The review found that SCS mitigate drug poisoning–related harm and unsafe drug use practices, facilitate uptake of substance use treatment and other health services, are associated with improvements in public order (e.g., A substantial body of peer-reviewed research demonstrates the positive impacts of SCS.

Drugs 52

Drugs Treatment Production Research 52

Drug Target Review

OCTOBER 24, 2023

Live Bacterial Products (LBPs) will provide patients with a desirable, credible, safe and effective treatment option. The human microbiome, a complex ecosystem of microorganisms residing within our bodies, has emerged as a promising frontier in the quest for innovative medical treatments.

Treatment 122

Treatment Pharmacokinetics Pharmaceuticals Production 122

The Pharma Data

OCTOBER 26, 2020

Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s experimental gene therapy program, PR001, for the treatment of neuronopathic Gaucher disease (nGD). In addition, the FDA has granted Fast Track designation for PR001 for the treatment of Parkinson’s disease with GBA1 mutations.

Disease 40

Disease FDA Treatment Therapies 40

Drug Target Review

OCTOBER 2, 2024

Cell and gene therapies (CGTs) have made significant advancements in treating oncological diseases, with therapies like CAR-T cell treatments transforming cancer care. By correcting these mutations, gene-modifying and editing therapies hold the promise of long-term, potentially curative treatments. 2017 May 31;58(3):435-440.

Therapies 52

Therapies Disease Engineering RNA 52

Drug Target Review

OCTOBER 17, 2023

To improve its treatment, early diagnosis and appropriate therapeutic strategies are very important. Metabolic changes such as increased arginine levels could serve as biomarkers for detecting cancer at an early stage, which is essential for successful cancer treatment and patient survival. 2017 July [cited 2023 October 9]; 3(2):45-51.

Regulations 98

Regulations Therapies Treatment Disease 98

The Pharma Data

NOVEMBER 2, 2020

adults by using blood pressure (BP) thresholds from the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) and the 2017 American College of Cardiology-American Heart Association (ACC-AHA) BP guidelines. adults) using the 2017 ACC-AHA guideline criteria.

Pharmaceuticals 52

Pharmaceuticals Treatment Disease Research 52

The Pharma Data

OCTOBER 18, 2020

(Janssen) has announced it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending the expanded use of Tremfya (R) (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA) in the European Union (EU). In July 2020, the U.S.

Treatment 40

Treatment Clinical Development Therapies Production 40

The Pharma Data

JANUARY 3, 2021

Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton, today announced that the U.S. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., BOSTON, Jan.

Clinical Trials 52

Clinical Trials Trials Treatment FDA 52

Common Sense for Drug Policy Blog

SEPTEMBER 9, 2023

Even among calls for a public health approach to opioids in North America, definitions range from those narrowly focused on population-level prevention via surveillance and research ( Joranson & Gilson, 2006 ) to expansive ones that include a commitment to the principles of social justice, human rights, and equity ( Emerson & Haden, 2021 ).

Treatment 40

Treatment Research Drugs 40

The Pharma Data

JANUARY 11, 2021

The agency previously granted the gene therapy Orphan Drug and Rare Pediatric Disease designations in 2017. Patients receiving the infusion did not achieve statistically significant muscle function following 48 weeks of treatment. Source link.

Therapies 52

Therapies Trials FDA Treatment 52

The Pharma Data

MAY 26, 2023

The new list also includes secondary prevention for rheumatic fever, acute and long-term management of asthma and chronic obstructive pulmonary disease as well as several cancer control interventions related to cervical, breast, colorectal, liver and childhood cancer, and the comprehensive treatment of cancer for those living with HIV.

Disease 52

Disease Government Treatment Production 52

The Pharma Data

NOVEMBER 19, 2020

percent during 2010 to 2017 (from 9.1 During 2017, the rates of HIV-related deaths were highest by race/ethnicity among persons of multiple races and Black/African American persons (7.0 The researchers found that death rates decreased by 36.6 percent overall during 2010 to 2018 (from 19.4 per 1,000 PWDH). to 4.7), while there was an 8.6

Treatment 52

Treatment Disease Research 52

The Pharma Data

DECEMBER 3, 2020

The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e.,

Treatment 52

Treatment Pharmaceutical Companies Therapies Virus 52

Drug Target Review

JULY 10, 2023

The world needs better treatments for neurodegenerative diseases and other brain disorders. As scientists continue to elucidate and advance novel drug targets and technology applications, the goal of bringing impactful treatments to patients becomes more of a reality. 2017 Dec 11;9(1). 2017 Sep 1;49(9):1373–84.

Research 52

Research Disease Treatment Drug Development 52

The Pharma Data

MARCH 4, 2021

Under the 2017 collaboration agreement, Takeda received equity in Ovid and was eligible to receive up to $85 million in payments for regulatory milestones, including the initiation of Phase 3 clinical trials. “We Advancing New Treatment Options for DS and LGS Patients.

Treatment 52

Treatment Clinical Trials Pharmaceutical Companies Trials 52

The Pharma Data

MAY 18, 2021

Health Canada approves DUPIXENT® (dupilumab injection) as the first biologic for the treatment of moderate-to-severe atopic dermatitis in children aged 6 to 11 years. 9 DUPIXENT ® is also approved in Canada for the treatment of adult patients with severe CRSwNP and for the treatment of severe asthma in patients 12 years and older.

Treatment 40

Treatment Disease Therapies Production 40

Broad Institute

OCTOBER 4, 2023

AbbVie and Calico discovered the molecule, called ABBV-CLS-484 , after TIDE researchers at Broad identified the PTPN2 gene as a promising cancer immunotherapy target in 2017. It still sort of stuns me that we went from discovering a target in 2017 to testing drugs in patients starting in 2020,” Yates said.

Small Molecule 128

Small Molecule Clinical Trials Engineering Trials 128

The Pharma Data

SEPTEMBER 9, 2020

The company is testing higher doses of Ocrevus against both relapsing MS and primary progressive MS while also studying the treatment in minority populations. Roche is hoping to defend its franchise against MS treatments from its competitors. Conor Kavanagh. Source link.

Trials 52

Trials Clinical Trials Treatment FDA 52